Are clinical trials into emerging drugs for the treatment of alpha-1 antitrypsin deficiency providing promising results?

References

• Gadek JE, Fells GA, Zimmerman RL, et al. Antielastases of the human alveolar structures. Implications for the protease-antiprotease theory of emphysema. J Clin Invest. 1981 Oct;68(4):889–898.
   PubMed Web of Science ®Google Scholar
• Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med. 1987 Apr 23;316(17):1055–1062. doi: 10.1056/NEJM198704233161704
   PubMed Web of Science ®Google Scholar
• CSLBehring. Respreeza summary of product characteristics. 2015.
   Google Scholar
• Soy D, de la Roza C, Lara B, et al. Alpha-1-antitrypsin deficiency: optimal therapeutic regimen based on population pharmacokinetics. Thorax. 2006 Dec;61(12):1059–1064.
   PubMed Web of Science ®Google Scholar
• Zamora NP, Pla RV, Del Rio PG, et al. Intravenous human plasma-derived augmentation therapy in alpha 1-antitrypsin deficiency: from pharmacokinetic analysis to individualizing therapy. Ann Pharmacother. 2008 May;42(5):640–646.
   PubMed Web of Science ®Google Scholar
• Chapman KR, Burdon JG, Piitulainen E, et al. Intravenous augmentation treatment and lung density in severe alpha1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jul 25;386(9991):360–368. doi: 10.1016/S0140-6736(15)60860-1
   PubMed Web of Science ®Google Scholar
• McElvaney NG, Burdon J, Holmes M, et al. Long-term efficacy and safety of alpha1 proteinase inhibitor treatment for emphysema caused by severe alpha1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). Lancet Respir Med. 2017 Jan;5(1):51–60. doi: 10.1016/S2213-2600(16)30430-1
   PubMed Web of Science ®Google Scholar
• Dirksen A, Piitulainen E, Parr DG, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J. 2009 Jun;33(6):1345–1353. doi: 10.1183/09031936.00159408
   PubMed Web of Science ®Google Scholar
• Green CE, Parr DG, Edgar RG et al. Lung density associates with survival in alpha 1 antitrypsin deficient patients. Respir med. 2016 Mar;112:81–87. doi: 10.1016/j.rmed.2016.01.007
   PubMed Web of Science ®Google Scholar
• Crossley D, Renton M, Khan M, et al. CT densitometry in emphysema: a systematic review of its clinical utility. Int J Chron Obstruct Pulmon Dis. 2018;13:547–563. doi: 10.2147/COPD.S143066
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence: Guidelines. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. In: Health and care excellence (NICE) copyright © NICE 2018. London: National Institute for; 2019. https://www.nice.org.uk/guidanceng115evidencefull-guideline-pdf-6602767453page2
   Google Scholar
• Miravitlles M, Dirksen A, Ferrarotti I, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α 1 -antitrypsin deficiency. Eur Respir J. 2017 Nov;50(5):1700610.
   PubMed Web of Science ®Google Scholar
• Sandhaus RA, Turino G, Brantly ML, et al. The diagnosis and management of alpha-1 antitrypsin deficiency in the adult. Chronic Obstr Pulm Dis. 2016 Jun 6;3(3):668–682. doi: 10.15326/jcopdf.3.3.2015.0182
   PubMed Web of Science ®Google Scholar
• Piitulainen E, Bernspang E, Bjorkman S, et al. Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human alpha(1)-antitrypsin. Eur J Clin Pharmacol. 2003 Jun;59(2):151–156.
   PubMed Web of Science ®Google Scholar
• Sieluk J, Slejko JF, Silverman H, et al. Medical costs of alpha-1 antitrypsin deficiency-associated COPD in the United States. Orphanet J Rare Dis. 2020 Sep 23;15(1):260. doi: 10.1186/s13023-020-01523-4
   PubMed Web of Science ®Google Scholar
• Kropp J, Wencker M, Hotze A, et al. Inhalation of [123I]alpha1-protease inhibitor: toward a new therapeutic concept of alpha1-protease inhibitor deficiency? J Nucl Med. 2001 May;42(5):744–751.
   PubMed Web of Science ®Google Scholar
• Stocks JM, Brantly ML, Wang-Smith L, et al. Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha1-antitrypsin deficiency: a randomized study. BMC Clin Pharmacol. 2010 Sep 30;10(1):13. doi: 10.1186/1472-6904-10-13
   PubMedGoogle Scholar
• Seyama K, Suzuki M, Tasaka S, et al. Long-term safety of Prolastin(R)-C, an alpha1-proteinase inhibitor, in Japanese patients with alpha1-antitrypsin deficiency. Respir Investig. 2022 Nov;60(6):831–839.
   PubMed Web of Science ®Google Scholar
• Campos MA, Kueppers F, Stocks JM, et al. Safety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK). COPD: J Chronic Obstructive Pulmonary Dis. 2013 Dec;10(6):687–695.
   PubMed Web of Science ®Google Scholar
• Bnpo S. Takeda. GLASSIA safety, immunogenicity, and bronchoalveolar lavage study. 2016. Available from: https://classic.clinicaltrials.gov/show/NCT02525861
   Google Scholar
• LLC GT. Efficacy and safety of Alpha1-proteinase inhibitor (human), modified process (alpha-1 MP) in subjects with pulmonary emphysema due to Alpha1 antitrypsin deficiency (AATD). 2013. Available from: https://classic.clinicaltrials.gov/show/NCT01983241
   Google Scholar
• LLC GT. A study to evaluate safety, tolerability and pharmacokinetics of two different doses of Alpha1-proteinase inhibitor subcutaneous (human) 15% in participants with Alpha1-antitrypsin deficiency. 2021. Available from: https://classic.clinicaltrials.gov/show/NCT04722887
   Google Scholar
• Behring C. Respreeza self-administration and learning program (AmAretti study). 2019. Available from: https://classic.clinicaltrials.gov/show/NCT04262284
   Google Scholar
• Inhibrx I. Study of INBRX-101 compared to plasma-derived A1PI therapy in adults with AATD emphysema. 2023. Available from: https://classic.clinicaltrials.gov/show/NCT05856331
   Google Scholar
• Corp HB. Study of OsrhAAT or Placebo in Healthy Volunteers. 2022. Available from: https://classic.clinicaltrials.gov/show/NCT05315921
   Google Scholar
• Petrache I, Hajjar J, Campos M. Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency. Biologics. 2009;3:193–204. doi: 10.2147/BTT.S4414
   PubMedGoogle Scholar
• Kamada L. Phase II, safety and efficacy study of Kamada-alpha-1-antitrypsin (AAT) for inhalation. 2014. Available from: https://classic.clinicaltrials.gov/show/NCT02001688;
   Google Scholar
• Kamada L, Health S. Evaluate efficacy and safety of “Kamada-AAT for inhalation” in patients with AATD. 2019. Available from: https://classic.clinicaltrials.gov/show/NCT04204252
   Google Scholar
• Rabbie S, Black I, Inshaw J. Analysis from phase II clinical trial, alvelestat, NE (Neutrophil Elastase) inhibitor in AATD-LD: correlation between biomarker response (desmosine and Aa-val360) and clinical outcome (SGRQ). B22. New treatments and novel targets for COPD and ALPHA-1. 2023. A2844–A2844.
   Google Scholar
• UoAa B, NIo H, BioPharma M. Alvelestat (MPH966) for the treatment of ALpha-1 ANTitrypsin deficiency. 2019. Available from: https://classic.clinicaltrials.gov/show/NCT03679598
   Google Scholar
• Watz H, Nagelschmitz J, Kirsten A, et al. Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: a randomized controlled trial. Pulm Pharmacol Ther. 2019 Jun 01;56:86–93.
   PubMed Web of Science ®Google Scholar
• A study of safety, tolerability, and pharmacokinetics of single doses of PHP-303 in healthy subjects. Available from: https://classic.clinicaltrials.gov/show/NCT03627845
   Google Scholar
• Incorporated VP. A phase 1, first-in-human study of VX-634. 2022. Available from: https://classic.clinicaltrials.gov/show/NCT05579431
   Google Scholar
• Limited ZF, Research HM, Plc CP. A single ascending and repeated dose study of oral ZF874 in healthy volunteers and PiXZ subjects. 2020. Available from: https://classic.clinicaltrials.gov/show/NCT04443192
   Google Scholar
• Incorporated VP. A study to evaluate efficacy and safety of VX-864 in participants with the PiZZ genotype. 2023. Available from: https://classic.clinicaltrials.gov/show/NCT05643495
   Google Scholar
• Incorporated VP. Evaluation of the efficacy and safety of VX-814 in subjects with the PiZZ genotype. 2020. Available from: https://classic.clinicaltrials.gov/show/NCT04167345
   Google Scholar
• Incorporated VP. Evaluation of the efficacy and safety of VX-864 in subjects with the PiZZ genotype. 2020. Available from: https://classic.clinicaltrials.gov/show/NCT04474197;
   Google Scholar
• Adverum Biotechnologies I. Safety dose finding study of ADVM-043 Gene therapy to treat alpha-1 antitrypsin (A1AT) deficiency. 2017. Available from: https://classic.clinicaltrials.gov/show/NCT02168686
   Google Scholar
• Adverum Biotechnologies I. Long-term follow-up study of ADVM-043. 2018. Available from: https://classic.clinicaltrials.gov/show/NCT03804021
   Google Scholar
• Beam therapeutics presents preclinical data highlighting utility of BEAM-302 to correct an alpha-1 antitrypsin (AAT) deficiency disease-causing mutation [Internet]. 2023. Available from: https://investors.beamtx.com/node/8731/pdf
   Google Scholar
• Intellia. Intellia therapeutics announces Second Quarter 2023 financial results and highlights recent company progress. 2023.
   Google Scholar
• Wave life sciences announces submission of first clinical trial application for WVE-006, the first-ever RNA editing clinical Candidate, and plans for upcoming virtual “R&D day” [Internet]. 2023. Available from: https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announces-submission-first-clinical-trial
   Google Scholar
• Strnad P, Mandorfer M, Choudhury G, et al. Fazirsiran for liver disease associated with Alpha(1)-antitrypsin deficiency. N Engl J Med. 2022 Aug 11;387(6):514–524. doi: 10.1056/NEJMoa2205416
   PubMed Web of Science ®Google Scholar
• Dicerna Pharmaceuticals I, a Novo Nordisk Company. A study of Belcesiran in patients with AATLD. 2021. Available from: https://classic.clinicaltrials.gov/show/NCT04764448
   Google Scholar